文献速递临床试验与 GCP流行病学与生物统计

南非开普敦启动抗逆转录病毒治疗者服药依从性监测与支持干预评估方案:采用析因设计的多阶段优化策略(MOST)

Protocol for an evaluation of adherence monitoring and support interventions among people initiating antiretroviral therapy in Cape Town, South Africa-a multiphase optimization strategy (MOST) approach using a fractional factorial design.
PubMed 文献 · Trials · 2023-05-05

南非开普敦三所诊所招募512名启动抗逆转录病毒治疗者,采用部分析因设计随机分配至16种干预组合,评估三种监测成分与两种支持成分的组合。主要结局为24个月病毒抑制(<50拷贝/mL),并评估可接受性、可行性、保真度与成本效果,以确定资源有限地区可推广的最优干预包。

要点

  • 采用MOST框架与部分析因设计,同时评估多个依从性干预成分及其组合。
  • 16种干预组合由3种监测成分与2种支持成分的不同组合构成。
  • 主要结局为24个月病毒抑制(<50拷贝/mL),并评估实施结局与成本效果。

核心结论

  • 本研究旨在确定资源有限地区诊所中疗效与成本效果最高、可行且可接受的HIV服药依从性监测与支持干预组合。
  • 据作者所知,本研究将是首个使用MOST框架确定资源有限地区HIV依从性监测与支持干预成分最有效组合的研究。
  • 研究结果将为务实、持续的依从性支持提供方向,作者认为这对终结HIV流行至关重要。

研究设计与样本

  • 采用部分析因设计,识别最有前景的干预成分,以纳入未来随机对照试验测试的多成分干预包。
  • 2022年3月至2024年2月在三所开普敦诊所招募512名启动抗逆转录病毒治疗的参与者。
  • 参与者被随机分配至16种条件之一,这些条件由三种依从性监测成分和两种依从性支持成分的不同组合构成。
  • 三种监测成分为:病毒未抑制后快速外展、药房取药遗漏后快速外展、电子依从性监测装置检测到漏服剂量后快速外展。
  • 两种支持成分为:每周签到短信和增强同伴支持。

主要发现

  • 主要结局为24个月时病毒抑制(<50拷贝/mL)。
  • 将评估可接受性、可行性、保真度及其他实施结局和成本效果。
  • 将使用逻辑回归模型以意向性治疗方式估计干预效果,并采用描述性统计评估实施结局。

关键数值与推荐

  • 病毒抑制定义为<50拷贝/mL。
  • 将确定最优干预包。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: South Africa bears a large HIV burden with 7.8 million people with HIV (PWH). However, due to suboptimal antiretroviral therapy (ART) adherence and retention in care, only 66% of PWH in South Africa are virally suppressed. Standard care only allows for suboptimal adherence detection when routine testing indicates unsuppressed virus. Several adherence interventions are known to improve HIV outcomes, yet few are implemented in routinely due to the resources required. Therefore, determining scalable evidence-based adherence support interventions for resource-limited settings (RLS) is a priority. The multiphase optimization strategy (MOST) framework allows for simultaneous evaluation of multiple intervention components and their interactions. We propose to use MOST to identify the intervention combination with the highest levels of efficacy and cost-effectiveness that is feasible and acceptable in primary care clinics in Cape Town. METHODS: We will employ a fractional factorial design to identify the most promising intervention components for inclusion in a multi-component intervention package to be tested in a future randomized controlled trial. We will recruit 512 participants initiating ART between March 2022 and February 2024 in three Cape Town clinics and evaluate acceptability, feasibility, and cost-effectiveness of intervention combinations. Participants will be randomized to one of 16 conditions with different combinations of three adherence monitoring components: rapid outreach following (1) unsuppressed virus, (2) missed pharmacy refill collection, and/or (3) missed doses as detected by an electronic adherence monitoring device; and two adherence support components: (1) weekly check-in texts and (2) enhanced peer support. We will assess viral suppression (<50 copies/mL) at 24 months as the primary outcome; acceptability, feasibility, fidelity, and other implementation outcomes; and cost-effectiveness. We will use logistic regression models to estimate intervention effects with an intention-to-treat approach, employ descriptive statistics to assess implementation outcomes, and determine an optimal intervention package. DISCUSSION: To our knowledge, ours will be the first study to use the MOST framework to determine the most effective combination of HIV adherence monitoring and support intervention components for implementation in clinics in a RLS. Our findings will provide direction for pragmatic, ongoing adherence support that will be key to ending the HIV epidemic. TRIAL REGISTRATION: ClinicalTrials.gov NCT05040841. Registered on 10 September 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jennings L, West RL, Halim N, et al. Protocol for an evaluation of adherence monitoring and support interventions among people initiating antiretroviral therapy in Cape Town, South Africa-a multiphase optimization strategy (MOST) approach using a fractional factorial design. Trials. 2023. PMID: 37147725. doi:10.1186/s13063-023-07322-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。